((自动化翻译由路透提供，请见免责声明 ))
1月10日 - ** 摩根士丹利（Morgan Stanley）将药物开发商Vir Biotechnology 的评级从 "等权重 "上调至 "增持"，理由是其T细胞吸引器(TCE) 技术的早期试验数据前景看好。
** 券商还将该股的目标价从10美元上调至20美元，较周三收盘价上涨60.3%。
**TCE 技术利用抗体靶向肿瘤细胞，同时激活 T 细胞，帮助免疫系统消灭癌细胞。
** 周三， (link)，VIR公司使用该技术的药物VIR-5818和VIR-5500在早期试验中对各种实体瘤患者产生了所谓的 令人信服的反应。
** 经纪公司称，这些药物不会引起 高级细胞因子释放综合征$(CRS)$，支持加大剂量和减少用药频率
** 当免疫系统反应过度并释放过多化学物质导致炎症时，就会出现 CRS。
** 9 家券商中有 7 家将该股评为 "买入 "或更高评级，2 家为 "持有"；它们的 PT 中值为 20 美元 - LSEG
** 2024 年 VIR 下降 ~30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.